Mike Pellini, MD, is a Managing Partner of Section 32.
Mike served as CEO of Foundation Medicine (NASDAQ:FMI), a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient (NASDAQ:CLRT), a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.
As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Mike brings a breadth of understanding in personalized medicine with a particular interest and focus in cancer. He is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health as well as the Advisory Board for Mission Hospital’s Cancer Institute (Providence/St. Joseph’s Health).
He also currently serves as a member of the board of directors for Thrive Earlier Detection, Nusano, Tango Therapeutics, Singular Genomics, Octave Bioscience, Vineti, Adaptive Biotechnologies, the Personalized Medicine Coalition, and the Mission Hospital Foundation.
Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.